Plasmapheresis: a Multi-modal Approach
NCT05815615 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70
Last updated 2023-04-18
Summary
Only very few studies have prospectively looked at the effect of repeated intensive plasma donation. In collaboration with the Rode Kruis Vlaanderen, we have recently found that repeated whole blood donation with a 3-month interval in between induced a drop in markers for iron status, which worsened with the number of donations. The repetition effect of the donations, whether whole blood or plasma, can be different from the effects measured after one single donation. It is therefore critical to test and document this repetitive effect to build trustable and valid guidelines concerning repetitive plasma donation.
Conditions
- Plasmapheresis
- Haematology
- Sport Performance
- Body Composition
- Inflammation
- Immunology
- Adverse Events
Interventions
- DEVICE
-
Plasmapheresis
Plasma donation at different frequencies
Sponsors & Collaborators
-
Université Catholique de Louvain
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-03-01
- Primary Completion
- 2022-12-31
- Completion
- 2022-12-31
Countries
- Belgium
Study Locations
More Related Trials
-
Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors
NCT03405688 ·Status: COMPLETED ·Phase: NA
-
Plasma Hepcidin Response to Differently Dosed Iron Supplements
NCT04735848 ·Status: COMPLETED ·Phase: NA
-
Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization
NCT03405402 ·Status: COMPLETED ·Phase: NA
-
Treatment of Hemochromatosis
NCT00007150 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PICU Transfusion Study: Harmful Effects of Red Blood Cell Transfusions
NCT02087553 ·Status: COMPLETED
-
Iron Replacement in Blood Donors
NCT00327067 ·Status: COMPLETED
-
Impact of Iron Injection on Blood Donation
NCT03014921 ·Status: UNKNOWN ·Phase: NA
-
Study of Biological Markers in Children With Sickle Cell Disease
NCT04839159 ·Status: UNKNOWN ·Phase: NA
-
Effects of Transfusion of Older Stored Red Cells
NCT01534676 ·Status: TERMINATED ·Phase: NA
-
Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients
NCT05791591 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
NCT00061750 ·Status: COMPLETED ·Phase: PHASE3
-
IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
NCT05153278 ·Status: COMPLETED
-
Hemoglobin and Iron Recovery Study
NCT01555060 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
NCT00171301 ·Status: COMPLETED ·Phase: PHASE4
-
Iron Substitution in Blood Donors
NCT01519830 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Therapeutic Phlebotomies on the Triglycerides Concentration in Patients With Hypertriglyceridemia and Hyperferritinemia
NCT02526121 ·Status: COMPLETED ·Phase: NA
-
Full Assessment of Clinical Transfusion Support
NCT07094646 ·Status: COMPLETED
-
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
NCT05440838 ·Status: RECRUITING
-
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
NCT00067080 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge
NCT04920045 ·Status: TERMINATED ·Phase: NA
-
Intravenous High Dose Iron in Blood Donors
NCT01787526 ·Status: COMPLETED ·Phase: PHASE3
-
Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
NCT03288012 ·Status: UNKNOWN
-
Predisposing Factors for Liver Diseases in Patients With Chronic Hemolytic Anemia
NCT06743854 ·Status: NOT_YET_RECRUITING
-
The Israeli Trigger for Blood Transfusions in the ICU
NCT00413816 ·Status: UNKNOWN
-
Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia
NCT01374919 ·Status: COMPLETED ·Phase: NA